Aegros Revenue and Competitors

Macquarie Park, AUS

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aegros's estimated annual revenue is currently $30.4M per year.(i)
  • Aegros's estimated revenue per employee is $155,000

Employee Data

  • Aegros has 196 Employees.(i)
  • Aegros grew their employee count by 54% last year.

Aegros's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
Executive Director, Chief Quality and Regulatory Officer at Aegros InnovationsReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Marketing OfficerReveal Email/Phone
5
Head Technical ServicesReveal Email/Phone
6
Head Research and Development - Protein ChemistryReveal Email/Phone
7
Head Finance OperationsReveal Email/Phone
8
Senior Purchasing OfficerReveal Email/Phone
9
Head FP&AReveal Email/Phone
10
Director R&DReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$63.9M41228%N/AN/A
#2
$16.9M1099%N/AN/A
#3
$22.6M14621%N/AN/A
#4
$18.1M1176%N/AN/A
#5
$392M25294%N/AN/A
#6
$66.8M43139%N/AN/A
#7
$18.8M12127%N/AN/A
#8
$16.6M107-14%N/AN/A
#9
$2M1386%N/AN/A
#10
$18.3M11818%N/AN/A
Add Company

What Is Aegros?

At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do thanks to the Australian invented HaemaFrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final precommercial phase of a clinical trial of our Covid-19 hyperimmune in conjunction with a major Sydney hospital.

keywords:N/A

N/A

Total Funding

196

Number of Employees

$30.4M

Revenue (est)

54%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$37.3M234-4%N/A
#2
$39.9M279-54%$95.6M
#3
$68.1M29517%N/A
#4
$38.4M3077%N/A
#5
$35M32618%N/A